Magnetic Stimulation Therapy for Treating Vascular Depression
NCT ID: NCT00044798
Last Updated: 2013-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
132 participants
INTERVENTIONAL
2001-09-30
2008-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants in this study will be randomly assigned to 15 treatments of either rTMS or sham rTMS for 3 weeks. Following treatment, participants will receive citalopram for 9 weeks. Response rates to treatment; relapse rates; the size, number, and location of the vascular lesions; and the amount of regional brain atrophy will be measured. Improvements in activities of daily living, quality of life, and cognitive function will also be also measured.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Participants will receive treatment with repetitive transcranial magnetic stimulation and citalopram.
Repetitive transcranial magnetic stimulation (rTMS)
Participants will receive 15 treatments of rTMS over 3 weeks.
Citalopram
After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.
2
Participants will receive treatment with sham repetitive transcranial magnetic stimulation and citalopram.
Citalopram
After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.
Sham rTMS
Participants will receive 15 treatments of sham rTMS over 3 weeks.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Repetitive transcranial magnetic stimulation (rTMS)
Participants will receive 15 treatments of rTMS over 3 weeks.
Citalopram
After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.
Sham rTMS
Participants will receive 15 treatments of sham rTMS over 3 weeks.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hamilton Depression Rating Scale score of at least 18
* Depression that is associated with cerebrovascular disease
* Failed at least 1 treatment for vascular depression
51 Years
89 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Mental Health (NIMH)
NIH
University of Iowa
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
UIHC/Psychiatry
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Iowa Health Care
Iowa City, Iowa, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.